title: Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?
abstract: BACKGROUND
  Breast cancer subtypes (BCS) determined from immunohistochemical staining have been correlated with molecular subtypes and associated with prognosis and outcomes, but there are limited data correlating these BCS and axillary node involvement. This study was conducted to assess whether BCS predicted for nodal metastasis or was associated with other clinicopathologic features at presentation.
  
  
  METHODS
  Patients with stage I/II disease who underwent breast-conserving surgery and axillary surgical assessment with available tissue blocks underwent a institutional pathological review and construction of a tissue microarray. The slides were stained for estrogen receptor, progesterone receptor, and HER-2/neu (HER-2) for classification into BCS. Nodal involvement and other clinicopathologic features were analyzed to assess associations between BCS and patient and tumor characteristics. Outcomes were calculated a function of BCS.
  
  
  RESULTS
  The study cohort consisted of 453 patients (luminal A 48.6%, luminal B 16.1%, HER-2 11.0%, triple negative 24.2%), of which 22% (n=113) were node positive. There were no significant associations with BCS and pN stage, node positivity, or absolute number of nodes involved (p>0.05 for all). However, there were significant associations with subtype and age at presentation (p<0.001), method of detection (p=0.049), tumor histology (p<0.001), race (p=0.041), and tumor size (pT stage, p<0.001) by univariate and multivariate analysis. As expected, 10-year outcomes differed by BCS, with triple negative and HER-2 subtypes having the worse overall (p=0.03), disease-free (p=0.03), and distant metastasis-free survival (p<0.01).
  
  
  CONCLUSIONS
  There is a significant association between BCS and age, T stage, histology, method of detection, and race, but no associations to predict nodal involvement. If additionally validated, these findings suggest that BCS may not be a useful prognostic variable for influencing regional management considerations.
authors: Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.
authors: Tiffanie
authors: T
authors: Jones
authors: Hanmanth
authors: H
authors: Neboori
authors: H
authors: H
authors: Wu
authors: Qifeng
authors: Q
authors: Yang
authors: Bruce G
authors: BG
authors: Haffty
authors: Susan
authors: S
authors: Evans
authors: Susan
authors: S
authors: Higgins
authors: Meena S
authors: MS
authors: Moran
mesh_terms: D001943:Breast Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D018275:Carcinoma, Lobular / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D015996:Survival Rate; D064726:Triple Negative Breast Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000473:pathology
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
references: Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):35-42
references: 17855007
references: Hum Pathol. 2006 Sep;37(9):1217-26
references: 16938528
references: Eur J Surg Oncol. 2003 Jun;29(5):423-5
references: 12798744
references: Breast Cancer Res. 2010;12(4):207
references: 20804570
references: J Natl Cancer Inst. 2006 May 3;98(9):599-609
references: 16670385
references: Nature. 2000 Aug 17;406(6797):747-52
references: 10963602
references: Lancet. 2011 Nov 19;378(9805):1812-23
references: 22098854
references: Jpn J Clin Oncol. 2011 Oct;41(10):1162-7
references: 21903706
references: Breast Cancer Res Treat. 2011 Feb;126(1):185-92
references: 20711652
references: Clin Breast Cancer. 2008 Jun;8(3):249-56
references: 18650155
references: Ann Surg Oncol. 2010 Jun;17(6):1471-4
references: 20180029
references: Clin Breast Cancer. 2010 Feb;10(1):59-63
references: 20133260
references: J Am Coll Surg. 1999 Jun;188(6):586-95; discussion 595-6
references: 10359351
references: JAMA. 2006 Jun 7;295(21):2492-502
references: 16757721
references: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
references: 12829800
references: JAMA. 2011 Feb 9;305(6):569-75
references: 21304082
references: Clin Cancer Res. 2004 Aug 15;10(16):5367-74
references: 15328174
references: Cancer. 2011 May 1;117(9):1819-26
references: 21509759
references: Cancer. 2011 Apr 15;117(8):1602-11
references: 21472708
references: Breast Cancer Res. 2010;12(6):R99
references: 21092082
references: Breast Cancer Res Treat. 2009 Jan;113(1):181-7
references: 18264760
references: Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1304-8
references: 19386432
references: Ann Surg Oncol. 2010 Oct;17 Suppl 3:343-51
references: 20853057
references: ISRN Oncol. 2011;2011:527904
references: 22084733
references: Rev Med Chir Soc Med Nat Iasi. 2011 Jul-Sep;115(3):839-44
references: 22046796
references: J Natl Cancer Inst Monogr. 2011;2011(42):43-5
references: 21672896
references: Cancer. 2008 Nov 1;113(9):2565-74
references: 18816610
references: Breast Cancer Res. 2006;8(4):R34
references: 16846532
references: BMC Womens Health. 2011 Sep 30;11:44
references: 21961708
references: Hum Pathol. 2008 Feb;39(2):167-74
references: 18045647
references: PLoS One. 2011;6(5):e20297
references: 21655258
references: Oncology. 2011;80(5-6):341-9
references: 21791944
references: Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):814-20
references: 22208971
references: Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1056-63
references: 18676094
references: Lab Invest. 2000 Dec;80(12):1943-9
references: 11140706